Nutriband receives Canadian patent allowance for AVERSA abuse deterrent transdermal technology

NutriBand Inc.

Canadian Intellectual Property Office issued Notice of Allowance for patent CA 2937649 covering AVERSA transdermal abuse deterrent technology.
Patent adds to existing US and Mexico patents, providing IP protection across North America.
Lead product AVERSA Fentanyl estimated to have peak annual US sales potential of $80M-$200M.
AVERSA technology aims to deter abuse, diversion, and accidental exposure of opioids like fentanyl in transdermal patches.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.